{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:53:28Z","timestamp":1761893608281,"version":"build-2065373602"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":724,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2000,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    The evaluation of serum triglyceride levels has played an important role as an independent method for assessing the risk factor for coronary atherosclerosis. Fibrates, nicotinic acid, and omega\u20103 polyunsaturated fish oils are the pharmacological tools most used today against hypertriglyceridaemia. Acarbose is a pseudotetrasaccharide of microbial origin which exerts a competitive, selective and reversible inhibition of the intestinal \u03b1 glucoside\u2010hydrolase. We evaluated the efficacy and side\u2010effects of acarbose as a new and alternative drug in the treatment of hypertriglyceridaemia in non\u2010diabetic patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We enrolled 30 non\u2010diabetic patients (18 men, 12 women; mean age 59.23 \u00b1 6.27\u2003years) without a family history of diabetes mellitus affected by familial hypertriglyceridaemia. The study covered a total period of 6.5\u2003months: half of the patients were on 1.5\u2003months of \u2018run in\u2019 diet only followed by 5 months of therapeutic diet plus acarbose; and half were on the therapeutic diet plus placebo. We gave 30 dividable pills to all patients. The administration was as follows: half a pill before lunch and half a pill before dinner while on the \u2018run in\u2019 diet. Fifteen patients (group A) took acarbose while the reminder (group B) took a placebo (50\u2003mg of starch); these were distributed randomly and the test was double blind. The 20\u2003weeks of study were divided in five 4\u2010week periods. Fasting serum concentrations of total cholesterol, triglycerides, HDL\u2010cholesterol (HDL\u2010c), LDL\u2010cholesterol (LDL\u2010c) and glucose were determined at the starting of the study and after each treatment cycle. Glucose values were determined 2\u2003h after lunch at the beginning of the study and at the end of the first, third and fifth month of treatment. All parameters assessed have been analysed by anova.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The serum total cholesterol, LDL\u2010c levels observed in the two groups did not change during the course of treatment. We observed a noteworthy progressive reduction of mean baseline triglyceride levels until the fourth month (p\u2003&lt;\u20030.05) in acarbose\u2010treated patients, with an increase in HDL\u2010c (p\u2003&lt;\u20030.008).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    We maintain that acarbose may be a useful therapeutic tool in addition to the diet in order to reduce triglyceride serum levels in non\u2010diabetic patients.\n                  <\/jats:p>","DOI":"10.1046\/j.1463-1326.2000.00065.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T09:58:58Z","timestamp":1047376738000},"page":"33-38","source":"Crossref","is-referenced-by-count":12,"title":["Treatment of familial hypertriglyceridaemia with acarbose"],"prefix":"10.1111","volume":"2","author":[{"given":"M.","family":"Malaguarnera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Giugno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ruello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Maugeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pistone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043798-199604000-00014"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(76)90089-5"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111422"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-12-199412150-00004"},{"key":"e_1_2_5_7_2","unstructured":"Muller L&Puls W.Pharmacology of alpha\u2010glucosidase inhibitors. In:Caspary WF.eds.Structure and Function of the Small Intestine. Amsterdam: Excepta Med. 1988:281300."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.6.817"},{"key":"e_1_2_5_9_2","first-page":"435","article-title":"Beneficial effects on serum lipids in non\u2010insulin dependent diabetics by acarbose treatment","volume":"41","author":"Leonhardt W","year":"1991","journal-title":"Drug Res"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198835030-00003"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01851237"},{"key":"e_1_2_5_12_2","first-page":"393","article-title":"Changes in plasma lipoprotein levels during medication with a glucosidase\u2010hydrolase inhibitor (acarbose)","volume":"7","author":"Homma Y","year":"1982","journal-title":"Tokai J Exp Med"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(81)90125-6"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198903163201105"},{"key":"e_1_2_5_15_2","first-page":"441","article-title":"Beneficial effects of acarbose on familiar hypertriglyceridemias","volume":"36","author":"Malaguarnera M","year":"1998","journal-title":"Clin Pharm Therap"},{"key":"e_1_2_5_16_2","first-page":"403","article-title":"Enzymatische Bestimmung des Gesamtcholesterins in Serum","volume":"12","author":"Roschlau P","year":"1974","journal-title":"Chem Klin Biochem"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-091304-6.50036-7"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/clinchem\/23.5.882","article-title":"Cholesterol determination in high density lipoproteins separated by three different methods","volume":"23","author":"Lopez\u2010Virella MF","year":"1977","journal-title":"Clin Chem"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(87)90188-4"},{"key":"e_1_2_5_20_2","first-page":"119","article-title":"Index of coronary artery atherogenesis","volume":"21","author":"Gofman J","year":"1953","journal-title":"Mod Med"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1959.00270010010002"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.12.11.1336"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-199404000-00006"},{"key":"e_1_2_5_24_2","first-page":"1220","article-title":"Plasma triglyceride level and mortality from coronary heart disease","volume":"17","year":"1993","journal-title":"New Engl J of Med"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1982.tb01978.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113490"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00038.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1463-1326.2000.00065.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1046\/j.1463-1326.2000.00065.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:22:37Z","timestamp":1761862957000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1046\/j.1463-1326.2000.00065.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1046\/j.1463-1326.2000.00065.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1463-1326.2000.00065.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}